Predictors of quality of life in inpatients with schizophrenia

Fujimaki, Koichiro; Morinobu, Shigeru; Yamashita, Hidehisa; Takahashi, Terumichi; Yamawaki, Shigeto

doi:10.1016/j.psychres.2011.10.023

Cited by 32 publications

(26 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…'' 7 Several studies have examined the associations between quality of life and cognitive deficits in schizophrenia. [8][9][10][11][12] However, probably because a variety of instruments have been used to evaluate quality of life, the results have varied between studies. A higher association between cognitive impairment and quality of life has been obtained with the use of objective quality of life scales rated by researchers than with measures of subjective quality of life in patient-reported outcomes.…”

Section: Introductionmentioning

confidence: 99%

Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms

Cruz

Resende

Carvalhaes³

et al. 2016

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: To analyze the correlation between quality of life, symptoms, and cognition assessed by the interview-based Schizophrenia Cognition Rating Scale (SCoRS). Methods: Seventy-nine outpatients diagnosed with schizophrenia were evaluated with the Quality of Life Scale -Brazilian version (QLS-BR), the SCoRS, and symptoms scales (Positive and Negative Syndrome Scale [PANSS]). After determining the potential explanatory variables using Spearman's correlation and Student's t test results, we ran simple, multivariate, and decision-tree regression analyses to assess the impact of SCoRS and PANSS ratings on mean overall quality of life. Results: Cognitive deficits and negative symptoms were the best predictors of quality of life. A low degree of negative symptoms (PANSS negative o 11) was a strong predictor of better quality of life (QLS B 75), regardless of SCoRS rating. Among participants with more severe negative symptoms, elevated cognitive impairment (interviewer SCoRS B 44) was a predictor of worse quality of life (QLS B 44). Conclusions: Cognitive impairment determined by interview-based assessment seems to be a strong predictor of quality of life in subjects with severe negative symptoms. These results support the usefulness of SCoRS for cognitive assessment that is relevant to the everyday life of patients with schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 99%

Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms

Cruz

Resende

Carvalhaes³

et al. 2016

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…In the past years, QOL has become an important outcome measure for those patients, although the associations between predictors and QOL are rather unclear. Several cross-sectional studies have investigated the relationship between the subjective QOL of people with severe mental disorders and socio-demographic and clinical characteristics (Norman et al, 2000;Fitzgerald et al, 2001;Becchi et al, 2004;Caron et al, 2005aCaron et al, , 2005bHofer et al, 2006;Narvaez et al, 2008;Hsiao et al, 2012;Fujimaki et al, 2012). In addition, some studies have explored the mediating role of self-related factors, such as lower self-esteem, lack of perceived social support and low self-efficacy in QOL appraisal (Bechdolf et al, 2003;Ritsner et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

The effect of service satisfaction and spiritual well-being on the quality of life of patients with schizophrenia

Lanfredi

Candini

Buizza

et al. 2014

Psychiatry Research

View full text Add to dashboard Cite

a b s t r a c tQuality of life (QOL) has been considered an important outcome measure in psychiatric research and determinants of QOL have been widely investigated. We aimed at detecting predictors of QOL at baseline and at testing the longitudinal interrelations of the baseline predictors with QOL scores at a 1-year follow-up in a sample of patients living in Residential Facilities (RFs). Logistic regression models were adopted to evaluate the association between WHOQoL-Bref scores and potential determinants of QOL. In addition, all variables significantly associated with QOL domains in the final logistic regression model were included by using the Structural Equation Modeling (SEM). We included 139 patients with a diagnosis of schizophrenia spectrum. In the final logistic regression model level of activity, social support, age, service satisfaction, spiritual well-being and symptoms' severity were identified as predictors of QOL scores at baseline. Longitudinal analyses carried out by SEM showed that 40% of QOL follow-up variability was explained by QOL at baseline, and significant indirect effects toward QOL at follow-up were found for satisfaction with services and for social support. Rehabilitation plans for people with schizophrenia living in RFs should also consider mediators of change in subjective QOL such as satisfaction with mental health services.

show abstract

“…The presence of negative symptoms, psychological discomfort, and resistance are powerful predictors of impaired quality of life 60. In addition, negative symptoms correlate with caregiver burden and distress 61–63…”

Section: Assessment Of Negative Symptomsmentioning

confidence: 99%

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options

Chue¹,

Lalonde

2014

NDT

View full text Add to dashboard Cite

The negative symptoms of schizophrenia represent an impairment of normal emotional responses, thought processes and behaviors, and include blunting or flattening of affect, alogia/aprosody, avolition/apathy, anhedonia, and asociality. Negative symptoms contribute to a reduced quality of life, increased functional disability, increased burden of illness, and poorer long-term outcomes, to a greater degree than positive symptoms. Primary negative symptoms are prominent and persistent in up to 26% of patients with schizophrenia, and they are estimated to occur in up to 58% of outpatients at any given time. Negative symptoms respond less well to medications than positive symptoms, and to date treatment options for negative symptoms have been limited, with no accepted standard treatment. Modest benefits have been reported with a variety of different agents, including second-generation antipsychotics and add-on therapy with antidepressants and other pharmacological classes. Recent clinical research focusing on negative symptoms target novel biological systems, such as glutamatergic neurotransmission. Different approaches include: enhancing N-methyl-D-aspartate receptor function with agents that bind directly to the glycine ligand site or with glycine reuptake inhibitors; influencing the metabotropic glutamate receptor (mGluR2/3) with positive allosteric modulators; and stimulating nicotinic acetylcholine receptors. In conclusion, the lack of clearly efficacious pharmacological treatments for the management of negative symptoms represents a significant unmet need, especially considering the importance of these symptoms on patient outcomes. Hence, further research to identify and characterize novel pharmacological treatments for negative symptoms is greatly needed.

show abstract

Predictors of quality of life in inpatients with schizophrenia

Cited by 32 publications

References 50 publications

Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms

Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms

The effect of service satisfaction and spiritual well-being on the quality of life of patients with schizophrenia

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options

Contact Info

Product

Resources

About